Stockscreener 앱 받기
20.64
0.58%
-0.12
시간 외 거래:
20.70
0.06
+0.29%
전일 마감가:
$20.76
열려 있는:
$22.08
하루 거래량:
41.52M
Relative Volume:
4.05
시가총액:
$4.76B
수익:
$1.07B
순이익/손실:
$18.10M
주가수익비율:
-121.41
EPS:
-0.17
순현금흐름:
$89.50M
1주 성능:
-7.19%
1개월 성능:
+16.87%
6개월 성능:
+83.30%
1년 성능:
+218.52%
1일 변동 폭
$19.54
$22.28
1주일 범위
$18.32
$22.28
52주 변동 폭
$6.23
$25.74
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025 - Investopedia
Hims & Hers Health (NYSE:HIMS) Announces Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat
Hims & Hers stock maintains buy rating with TD Cowen after 'solid 3Q24' - Investing.com
Truist reiterates hold rating on HIMS stock with $23 target post Q3 beat - Investing.com
Hims & Hers Health's (HIMS) "Neutral" Rating Reiterated at Piper Sandler - MarketBeat
Hims & Hers Stock Rises on Earnings, Generic Version of Novo Nordisk Diabetes Drug - Barron's
What's Going On With Hims & Hers Health Stock Tuesday? - Benzinga
Hims & Hers Health: Another Blowout Quarter Ignored (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health (NYSE:HIMS) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Revenue Soars 77% for Hims & Hers Health, Inc. in Q3 2024 - Happi
Hims & Hers Stock Soars: First Generic Weight Loss Drug to Shake Up Billion-Dollar Market - GuruFocus.com
Hims & Hers Reports High Success Rate in GLP-1 Program - Athletech News
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts - Yahoo Finance
Hims & Hers Health (HIMS) to Launch Generic Liraglutide for Weig - GuruFocus.com
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance - Barchart
Canaccord Genuity Group Increases Hims & Hers Health (NYSE:HIMS) Price Target to $28.00 - MarketBeat
Hims & Hers Health, Inc. (NYSE:HIMS) Q3 2024 Earnings Call Transcript - Insider Monkey
Hims & Hers to launch a generic for Novo’s older GLP-1 - MSN
Citi lifts Hims and Hers share price target on strong results - Investing.com
Hims and Hers stock gets boost from BofA as marketing spend fuels user growth - Investing.com
Hims & Hers defends compounded GLP-1s as shortages wane - Modern Healthcare
Earnings call: Hims & Hers reports robust Q3 growth, plans for expansion - Investing.com
Vanguard Group Inc's Strategic Acquisition in Hims & Hers Health Inc - GuruFocus.com
Hims & Hers Health Inc (HIMS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Hims & Hers Health Inc (HIMS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Hims & Hers Health Reports Strong Q3 2024 Growth - TipRanks
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow (HIMS) - Seeking Alpha
Hims & Hers Health Q3 earnings beat estimates, raises guidance - MSN
PLTR, DJT, HIMS, NXPI, TSLA: Top 5 Trending Stocks TodayHims & Hers Health (NYSE:HIMS), Trump Media & Technology (NASDAQ:DJT) - Benzinga
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’ - MSN
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates - MSN
Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences. - Yahoo Finance
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025 - Reuters
Hims & Hers shares rally on results, despite continued GLP-1 drug shortage - MarketWatch
Hims & Hers Stock Up Ahead of Earnings: Retail Sentiment Upbeat - MSN
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock? - MSN
Hims & Hers up 7% on raised 2024 revenue guidance, Q3 beats - Seeking Alpha
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details - Benzinga
Hims & Hers Health Raises Outlook, Swings to 3Q Profit - MarketWatch
Hims & Hers Health Q3 earnings beat estimates, raises guidance By Investing.com - Investing.com Canada
Hims & Hers Stock Up Ahead Of Earnings: Retail Sentiment Upbeat - Barchart
Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results - Business Wire
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Hims & Hers Health Inc (HIMS) Shares Up 3.71% on Nov 4 - GuruFocus.com
Hims & Hers Health, Inc. (HIMS) Stock Moves -1.1%: What You Should Know - MSN
Hims & Hers Health Inc (HIMS) Shares Up 6.33% on Nov 1 - GuruFocus.com
Learn to Evaluate (HIMS) using the Charts - Stock Traders Daily
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lil - GuruFocus.com
Hims & Hers Health (NYSE:HIMS) Stock Price Up 7.5%Still a Buy? - MarketBeat
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News - Yahoo Finance
36,840 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by International Assets Investment Management LLC - MarketBeat
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.12%
0.04%
자본화:
|
볼륨(24시간):